Online citations, reference lists, and bibliographies.
← Back to Search

The Schizophrenia Cognition Rating Scale: An Interview-based Assessment And Its Relationship To Cognition, Real-world Functioning, And Functional Capacity.

R. Keefe, Margaret P. Poe, Trina M. Walker, Joseph W. Kang, Philip D. Harvey
Published 2006 · Psychology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
OBJECTIVE Interview-based measures of cognition may serve as potential coprimary measures in clinical trials of cognitive-enhancing drugs for schizophrenia. However, there is no such valid scale available. Interviews of patients and their clinicians are not valid in that they are unrelated to patients' levels of cognitive impairment as assessed by cognitive performance tests. This study describes the reliability and validity of a new interview-based assessment of cognition, the Schizophrenia Cognition Rating Scale (SCoRS), that involves interviews with patients and informants. METHOD Sixty patients with schizophrenia were assessed with the SCoRS and three potential validators of an interview-based measure of cognition: cognitive performance, as measured by the Brief Assessment of Cognition in Schizophrenia (BACS); real-world functioning, as measured by the Independent Living Skills Inventory; and functional capacity, as measured by the University of California, San Diego, Performance-Based Skills Assessment (UPSA). RESULTS The SCoRS global ratings were significantly correlated with composite scores of cognitive performance and functional capacity and with ratings of real-world functioning. Multiple regression analyses suggested that SCoRS global ratings predicted unique variance in real-world functioning beyond that predicted by the performance measures. CONCLUSIONS An interview-based measure of cognition that included informant reports was related to cognitive performance as well as real-world functioning. Interview-based measures of cognition, such as the SCoRS, may be valid coprimary measures for clinical trials assessing cognitive change and may also aid clinicians desiring to assess patients' level of cognitive impairment.
This paper references
10.1001/ARCHPSYC.1991.01810310036007
Neuropsychological function in schizophrenia. Selective impairment in memory and learning.
A. Saykin (1991)
10.1176/AJP.153.3.321
What are the functional consequences of neurocognitive deficits in schizophrenia?
M. Green (1996)
10.1017/S1092852900005034
Cognitive Impairment in Schizophrenia and Implications of Atypical Neuroleptic Treatment
Philip D. Harvey (1997)
10.1037//0894-4105.12.3.426
Neurocognitive Deficit in Schizophrenia: A Quantitative Review of the Evidence
R. Heinrichs (1998)
10.1097/00005053-199806000-00007
Causal mechanisms of subjective cognitive dysfunction in schizophrenic and depressed patients.
R. J. van den Bosch (1998)
10.1080/10973439908408384
Functional Assessment of Independent Living Skills
A. Menditto (1999)
10.1093/OXFORDJOURNALS.SCHBUL.A033430
Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?
M. Green (2000)
Informant-rated cognitive symptoms in normal aging, mild cognitive impairment, and dementia. Initial development of an informant-rated screen (Brief Cognitive Scale) for mild cognitive impairment and dementia.
K. Krishnan (2001)
10.1093/OXFORDJOURNALS.SCHBUL.A006870
UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults.
T. Patterson (2001)
10.1097/00019442-200111000-00003
A regulatory perspective on psychiatric syndromes in Alzheimer disease.
T. Laughren (2001)
10.1053/COMP.2001.24587A
The convergence of neuropsychological testing and clinical ratings of cognitive impairment in patients with schizophrenia.
Philip D. Harvey (2001)
10.1016/S0010-440X(03)00086-5
Exploring cognitive complaints in schizophrenia: the subjective scale to investigate cognition in schizophrenia.
E. Stip (2003)
10.1016/j.biopsych.2004.06.023
Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria
M. Green (2004)
10.1038/nrn1433
Advances in the early detection of Alzheimer's disease
P. Nestor (2004)
10.1017/S1355617704104153
Memory and attention performance in psychiatric patients: Lack of correspondence between clinician-rated and patient-rated functioning with neuropsychological test results
S. Moritz (2004)
10.1097/01.nmd.0000130133.32276.83
Assessing Disability in Older Patients With Schizophrenia: Results From the WHODAS-II
C. McKibbin (2004)
10.1016/j.schres.2003.09.011
The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery
R. Keefe (2004)
10.1093/SCHBUL/SBI020
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.
R. Buchanan (2005)
10.1080/13803390500360539
The Relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to Functional Capacity and Real-world Functional Outcome
R. S. Keefe (2006)
10.1176/APPI.AJP.163.3.411
Barriers to employment for people with schizophrenia.
R. Rosenheck (2006)



This paper is referenced by
10.1002/wps.20809
The clinical characterization of the patient with primary psychosis aimed at personalization of management
M. Maj (2021)
10.1016/j.sjbs.2020.11.044
TULIP study: Trail of Lurasidone in bipolar disorder in Pakistan☆
Nasar Khan (2021)
10.1016/j.nicl.2021.102805
Potential contribution of pineal atrophy and pineal cysts toward vulnerability and clinical characteristics of psychosis
Tsutomu Takahashi (2021)
10.3390/jpm11050327
Prolonged P300 Latency in Antipsychotic-Free Subjects with At-Risk Mental States Who Later Developed Schizophrenia
Y. Higuchi (2021)
10.3389/fpsyt.2021.642048
Reduced Hippocampal Subfield Volume in Schizophrenia and Clinical High-Risk State for Psychosis
D. Sasabayashi (2021)
10.1016/j.euroneuro.2021.05.010
Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions
J. McCracken (2021)
10.1016/j.scog.2021.100207
Self-assessment of social cognition in a sample of Lebanese in-patients with schizophrenia
C. Haddad (2021)
10.3389/fdgth.2021.711941
Cognitive Impairments in Schizophrenia: A Study in a Large Clinical Sample Using Natural Language Processing
Aurelie Mascio (2021)
10.3389/fnbeh.2021.647069
Heschl’s Gyrus Duplication Pattern in Individuals at Risk of Developing Psychosis and Patients With Schizophrenia
Tsutomu Takahashi (2021)
10.3389/fpsyt.2020.00722
Cognitive Remediation Interventions in Autism Spectrum Condition: A Systematic Review
Y. Dandil (2020)
10.1007/s12311-020-01193-9
Efficacy of Intensive Cerebellar Intermittent Theta Burst Stimulation (iCiTBS) in Treatment-Resistant Schizophrenia: a Randomized Placebo-Controlled Study
P. Chauhan (2020)
10.1016/j.schres.2020.04.016
Thalamic and striato-pallidal volumes in schizophrenia patients and individuals at risk for psychosis: A multi-atlas segmentation study
Tsutomu Takahashi (2020)
10.18203/2349-3933.ijam20201618
Clinical efficacy and safety of lurasidone in schizophrenia: 8 week randomized double blind active controlled trial
U. Saxena (2020)
10.1007/s10803-020-04722-x
Cognitive and Social Cognitive Self-assessment in Autistic Adults.
Kilee M DeBrabander (2020)
10.1080/13546805.2020.1722084
Investigating subjective cognitive complaints in psychosis: Introducing the brief scale to Investigate cognition in schizophrenia (SSTICS-Brief)
M. Cella (2020)
10.1016/j.schres.2020.08.010
Factor structure of cognitive performance and functional capacity in schizophrenia: Evidence for differences across functional capacity measures
Philip D. Harvey (2020)
10.1016/j.psychres.2020.112891
Psychometric properties of the Observable Social Cognition Rating Scale (OSCARS): Self-report and informant-rated social cognitive abilities in schizophrenia
T. Halverson (2020)
10.11596/asiajot.16.29
Cost-Effectiveness of Individualized Occupational Therapy for Schizophrenia: Results from a Two-Year Randomized Controlled Trial
Takeshi Shimada (2020)
10.1007/s11065-020-09448-2
A Meta-Analysis of Neuropsychological Effort Test Performance in Psychotic Disorders
I. Ruíz (2020)
10.1038/s41598-020-73553-8
Brain structural correlates of functional capacity in first-episode psychosis
E. Alkan (2020)
10.1016/j.jpsychires.2020.12.062
Effects of aerobic walking on cognitive function in patients with schizophrenia: A randomized controlled trial.
Yu-Chi Huang (2020)
10.1016/j.scog.2020.100178
Evaluation of executive functions and everyday life for people with severe mental illness: A systematic review
S. Regev (2020)
10.1016/j.psychres.2020.113498
Interview and questionnaire assessment of cognitive impairment in subjects at ultra-high risk for psychosis: Associations with cognitive test performance, psychosocial functioning, and positive symptoms
L. Randers (2020)
10.1186/s12888-020-2459-y
Defining cognitive and functional profiles in schizophrenia and affective disorders
Yu-Chi Huang (2020)
10.1016/j.scog.2019.100161
The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures
M. Kraus (2020)
10.1016/j.psychres.2020.113027
Neuropsychological features in patients with severe mental disorders and risk of violence: A prospective multicenter study in Italy
E. Gobbi (2020)
10.1016/b978-0-12-815012-2.00008-0
Assessing Cognition and Social Cognition in Schizophrenia & Related Disorders
A. Pinkham (2020)
10.1016/j.psychres.2020.113404
Validity and utility of a set of clinical criteria for cognitive impairment associated with psychosis (CIAPs)
M. Cuesta (2020)
S0033291719000461jra 644..652
S. Moeller (2020)
10.30773/pi.2020.0085
Correlation between Performance-Based and Interview-Based Cognitive Measurements in Patients with Schizophrenia
D. Jeon (2020)
10.7717/peerj.7432
Defining cognitive profiles of depressive patients using the Brief Assessment of Cognition in Affective Disorders
Ruei-An Chen (2019)
10.31661/gmj.v8i0.1334
Effect of Cuscuta epithymum Acquainted with Risperidone on the Improvement of Clinical Symptoms and Cognitive Impairment in Patients with Schizophrenia: A Triple-Blind Randomized Placebo-Controlled Trial
M. Parvizi (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar